Galderma Research and Development, LLC
5 Cedar Brook Drive, Suite 1
About Galderma Research and Development, LLCGalderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 33 wholly-owned affiliates with a worldwide network of distributors and approximately 5,500 employees. Galderma’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic brands include Epiduo®, Oracea®, Clobex®, Differin®, Mirvaso®, Rozex®/MetroGel®, Silkis®/Vectical®, Tri-Luma®, Loceryl®, Cetaphil®, Metvix®, Azzalure®, Restylane® and Emervel®.
For more information, please visit Galderma’s website www.galderma.com.
7 articles with Galderma Research and Development, LLC
Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases
Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists
#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month
Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition
Galderma Receives FDA Approval For Restylane® Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth
Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Kysse for lip augmentation and the correction of upper perioral rhytids (wrinkles around upper lips) in adults over the age of 21.
Oncodesign (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is announcing a service partnership with Galderma, a dermatological unit belonging to Nestlé Skin Health.
Galderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'
Galderma released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin.
New Phase 4 OSCAR Trial Data Showed that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Decreased Acne Lesions Therefore Reducing the Risk of Scars in Moderate-to-Severe Acne Patients
Data Reinforces Importance of Scar Prevention as an Important Goal of Acne Treatment